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ABSTRACT 
Objective: To evaluate the cost-effectiveness of eltrombopag compared with romiplostim as a treatment 
for chronic immune thrombocytopenia (cITP) in patients who are splenectomized or ineligible for 
splenectomy and are treatment refractory in England and Wales. 
Methods: A Markov cohort model in which patients were administered a sequence of treatments was 
used to predict long-term outcomes associated with each treatment. The model was informed by data 
from the eltrombopag clinical trial program and the available literature. The analysis was conducted from 
the perspective of the United Kingdom National Health Service, and a lifetime time horizon was used. 
Deterministic and probabilistic sensitivity analyses were performed. 
Results: Eltrombopag dominated romiplostim (i.e., eltrombopag was as effective as but less costly than 
romiplostim) in both splenectomized and non-splenectomized patients, assuming a class effect for the 
two treatments. Eltrombopag also dominated romiplostim in the majority of deterministic sensitivity 
analyses with the exception of when indirect efficacy estimates were incorporated into the model. In this 
analysis, eltrombopag no longer dominated romiplostim but remained cost-effective versus romiplostim at 
a willingness-to-pay threshold of £20,000 per quality-adjusted life-year (QALY). Probabilistic sensitivity 
analysis demonstrated that there was a 99% and 92% chance of eltrombopag being cost-effective at a 
cost-effectiveness threshold of £20,000/QALY in splenectomized and non-splenectomized patients, 
respectively. 
Conclusions: Results of this study demonstrate that eltrombopag is cost-effective when compared to 
romiplostim as a treatment for cITP, representing good value for the United Kingdom National Health 
Service. 
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INTRODUCTION 
Primary immune thrombocytopenia (ITP) is a disease involving increased platelet destruction and 
impaired platelet production, leading to low platelet counts and impaired blood clotting (1, 2). The 
prevalence of ITP in the United Kingdom (UK) is 0.05% (3). Bleeding symptoms range from mild bruising 
to serious, potentially fatal, hemorrhage. Patients with ITP lasting >12 months are considered to have 
chronic ITP (cITP) (2). Patients with cITP are often unresponsive to one or more agents, and their disease 
is associated with significant morbidity, impaired quality of life, and increased mortality (4, 5). The goals of 
treatment are to reduce the risk of bleeding by elevating platelet counts while minimizing treatment-
related side effects (2).  
The management of ITP is complex (6). Following first-line treatment with corticosteroids or 
immunoglobulins (Ig), there is no clearly defined treatment pathway, and evidence from randomized 
controlled trials is scarce (6). Management of ITP is generally tailored to the individual patient depending 
on their symptoms, platelet count, lifestyle, and adverse events (AEs) associated with different therapies. 
Splenectomy is a potentially curative treatment option for cITP but is invasive, irreversible, and not 
appropriate for all patients (6). Patients typically cycle through several treatment options with differing 
lengths of response, some of which have significant side effects and most of which are not licensed 
treatments for ITP (6). Rescue treatments such as intravenous (IV) corticosteroids or IVIg may be given 
when a patient bleeds or is considered at high risk of bleeding (7). These are used either as an adjunct to 
WKHSDWLHQW¶VSULPDU\WKHUDS\RURQFHQRQ-rescue treatment options have been exhausted. 
Eltrombopag is an oral thrombopoietin receptor agonist (TPO-RA) that stimulates the proliferation and 
differentiation of megakaryocytes in the bone marrow, resulting in a dose-dependent increase in normal-
functioning platelet levels (8-10). Eltrombopag is licensed in the European Union (EU) for treatment of 
adult splenectomized patients with cITP who are refractory to other treatments and may also be 
considered as second-line treatment for adult non-splenectomized cITP patients where splenectomy is 
contraindicated (11).  
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In the phase 3 registration trial (Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura 
Study With Eltrombopag [RAISE]; ClinicalTrials.gov identifier: NCT00370331) comparing eltrombopag to 
placebo, eltrombopag produced clinically meaningful and statistically significant differences versus 
placebo as an addition to standard of care, achieiving the primary endpoint (odds of achieving a platelet 
count between 50±400×109/L) and prespecified bleeding endpoints (12). Furthermore, eltrombopag 
allowed patients to reduce their use of concomitant and rescue medications. An ongoing long-term 
extension study (Eltrombopag Extended Dosing Study [EXTEND]; NCT00351468), where some patients 
have now been followed for >5 years, confirms the long-term efficacy of eltrombopag in cITP and showed 
that eltrombopag is generally well tolerated (13, 14). 
Romiplostim, a peptibody TPO-RA that mimics thrombopoietin, is administered by weekly subcutaneous 
injection and was approved in the EU in 2009. Like eltrombopag, the studies leading to its approval were 
randomized controlled trials versus placebo or standard of care (15-17). In two parallel phase 3 studies of 
splenectomized or non-splenectomized patients, 83% of the combined study populations achieved a 
durable platelet response, which was GHILQHGDVZHHNO\SODWHOHWUHVSRQVHVDWDQy time during the 
study. Romiplostim and eltrombopag are licensed for identical populations by the European Medicines 
Agency (11, 18). 
Using available clinical data and the existing literature, an economic evaluation was designed to assess 
the cost-effectiveness of eltrombopag versus romiplostim among patients with cITP who previously 
underwent treatment with azathioprine, mycophenolate mofetil, cyclosporine, dapsone, danazol, 
cyclophosphamide, vincristine, and/or vinblastine (19, 20).  Patients at a high risk of bleeding or who 
require frequent rescue therapy were modelled.  Romiplostim is recommended by National Institute for 
Health and Care Excellence (NICE) and considered the standard of care amongst the patient group 
evaluated in this cost-effectiveness analysis. The model underpinning the current analysis informed the 
NICE appraisal of eltrombopag.  
METHODS 
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This de novo economic evaluation was designed to assess the cost-effectiveness of treatment with 
eltrombopag compared with romiplostim in two patient populations: (1) adult splenectomized cITP 
patients who are refractory to other treatments (e.g., corticosteroids, IVIg) and (2) adult non-
splenectomized cITP patients who are refractory to other treatments (e.g., corticosteroids, IVIg) and in 
whom splenectomy is contraindicated. Previous interventions in these patients included corticosteroids, 
which were the most frequently reported prior treatment in RAISE, immunoglobulins, splenectomy, 
rituximab, cyclophosphamide, and romiplostim. The total number of previous treatments for cITP 
administered to study participants is shown in Table 1 (12). These patient groups are within the marketing 
authorizations in the EU for both TPO-RAs. Additionally, these patients are within those included in the 
RAISE trial. The current evaluation intends to represent the experience of those patients at a high risk of 
bleeding who required frequent rescue therapy.  
The model assumed that patients receive a series of cITP treatments following their treatment with 
eltrombopag or romiplostim. This treatment sequence consisted of azathioprine, mycophenolate mofetil, 
cyclosporine, dapsone, danazol, cyclophosphamide, vincristine, and vinblastine. If a patient fails the 
current treatment, he or she is moved to the next treatment in the sequence. Patients were assumed to 
have a specific probability of receiving each treatment in the pathway (Supplemental Material). These 
probabilities were derived from a physician survey conducted by the romiplostim manufacturer and taken 
from the PDQXIDFWXUHU¶VVXEPLVVLRQIRUWhe NICE appraisal of romiplostim (21). Rituximab was not 
included in the base-case treatment sequence because it would predominantly be used prior to a TPO-
RA (19). 
A Markov cohort model was used to estimate the time spent in each of six health states for each 
treatment: a long-tHUPUHVSRQGHUVWDWHSODWHOHWV×109/L), a long-term non-responder state (platelets 
<50×10
9
/L), and four non-responder tunnel states of 4-ZHHNLQWHUYDOVWKDWZHUHXVHGWRPRGHODSDWLHQW¶V
time to response (Fig. 1). Transition between health states was dependent on response rate, time taken 
to respond, and duration of response for each treatment. Within each health state, patients faced a risk of 
experiencing an outpatient or inpatient bleed and an independent risk of requiring rescue treatment (IVIg, 
anti-D, IV corticosteroids, or platelet transfusion). Patients within the non-responder health state were 
 7 
 
assumed to start a new treatment if they experienced a bleed or failed rescue treatment. Once all 
treatment options along the pathway had been exhausted, patients were assumed to remain in the long-
term non-responder state. Patients could die from general or ITP-related causes from any health state.  
The analysis was conducted from the perspective of the UK National Health Service (NHS) in England 
and Wales with a lifetime time horizon. The model applied a discount rate of 3.5% for costs and benefits. 
The cycle length was 4 weeks (28 days), and a half cycle correction was applied.  
Model Inputs 
Systematic literature reviews of the clinical and economic literature were used to inform the model (19). 
This was supplemented by further analysis of patient-level data from the eltrombopag clinical trial 
program. Due to the paucity of data in cITP, where data could not be identified through systematic review, 
inputs were taken from the romiplostim manufacturer submission or the international consensus report on 
the investigation and management of primary ITP (20-22). 
Clinical Data 
Response Rates: The response rate for eltrombopag was derived from patient-level data from RAISE and 
reflects the primary endpoint definition of response (i.e., patients achieving a platelet count of 50±
400×10
9
/L) at assessments during the 6-month treatment period (patients who received rescue 
treatments were regarded as non-responders for the duration of rescue treatment and until platelet counts 
fell to <50×10
9
/L after ceasing rescue treatment) (12). An indirect treatment comparison (ITC) with 
romiplostim using this endpoint definition was not possible, as no such data were reported in the 
romiplostim trials. 
In the romiplostim trials, a response was defined as a platelet count >50×10
9
/L (15).
 
Platelet responses 
that occurred within 8 weeks after receiving rescue treatment were not included in the efficacy analysis. 
Durable platelet response was defined as weekly platelet responses for 6 of the last 8 weeks of 
treatment. Patients who received rescue medication at any time during the study were not counted as 
having a durable response. Transient response was defined as weekly platelet responses without a 
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durable platelet response from weeks 2 to 25. Overall platelet response was defined as durable plus 
transient rates of platelet response.  
Post-hoc data analyses from RAISE were available, which were more comparable with the romiplostim 
trial endpoints of durable and overall responses (12). In these analyses, durable/sustained response was 
GHILQHGDVDSODWHOHWFRXQWDQGî9/L for 6 of the last 8 weeks of the 26-week treatment 
period. Patients receiving rescue medication at any time and those who prematurely withdrew from the 
study were considered to have not achieved a durable/sustained response. Transient response was 
defined as a SODWHOHWFRXQWUHVSRQVHIRUFRQVHFXWLYHZHHNVGXULQJWUHDWPHQWDQGLQFOXGHGDOOGDWDXS
to the time of withdrawal for premature withdrawals. Overall response was defined as having either a 
durable/sustained response or a transient response (12). 
Some important differences in the design of RAISE and the romiplostim trials suggest that the data 
available for the two drugs are not entirely comparable. However, the broad similarities in the patient 
populations provided a reasonable justification for conducting an adjusted ITC using these post-hoc 
analyses for use in a sensitivity analysis. The Bucher technique (23) was applied for the adjusted ITC. 
This method maintains the randomization from each trial and provides estimates of the treatment effect 
for eltrombopag versus romiplostim (e.g., odds ratios [OR]) and 95% confidence intervals [CIs]) (Table 2). 
Analyses were conducted separately for splenectomized and non-splenectomized patients. Results of the 
ITC of response rates suggested no statistically significant differences between the two TPO-RAs 
regarding overall or durable responses for either splenectomized or non-splenectomized patients, 
evidenced by wide CIs that cross one.  
An ITC of bleeding events was also performed but was not used for the purpose of economic modeling. 
Due to the very small number of bleeding events, no significant differences were observed between 
eltrombopag and romiplostim, and point estimates had very wide CIs (data not shown). Differences in 
bleeding endpoint definitions also confounded this comparison. In order to inform long-term outcomes for 
this model, we estimated bleed rates conditional upon platelet level using data from RAISE and EXTEND 
as described below. It was assumed that these estimates were valid for both eltrombopag and 
romiplostim. 
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In the base case, the effectiveness of romiplostim was assumed to be the same as eltrombopag, and it 
was based on the response rates for eltrombopag observed in the RAISE trial. For non±TPO-RA 
treatments, only naïve comparisons were possible as no direct or comparative data with common control 
arms were available to perform an adjusted ITC. Weighted averages were taken from the systematic 
review and, where data were not stratified by splenectomy status, it was assumed that the proportion of 
splenectomized patients and the relative risk of response in splenectomized versus non-splenectomized 
patients was the same as for patients in RAISE. 
Time to Response: The modeled time to response for eltrombopag was derived from RAISE data and 
reflects the time at which the proportion of patients responding to eltrombopag stabilizes (Table 3) (12). 
For romiplostim, the maximum time from treatment initiation to initial response is assumed to be 4 weeks, 
reflecting that seen in the Kuter et al. trials (15). Time to response for non±TPO-RAs was taken from the 
systematic review and was not differentiated for splenectomized versus non-splenectomized patients, as 
insufficient data were available to inform these estimates. To avoid creating a large number of tunnel 
states in the model, any time to response for the non-TPO-RAs >4 cycles (16 weeks) was truncated at 16 
weeks. 
Time on Treatment: Time on treatment for eltrombopag was based on treatment cessation data from 
RAISE and EXTEND, where time on treatment for patients randomized to eltrombopag and classified as 
responders was modeled as a survival variable. An adjusted parametric analysis was conducted to 
analyze the effect of prior splenectomy and to enable estimation of time on treatment beyond the 
combined duration of RAISE and EXTEND. The log-normal distribution provided the best statistical fit to 
the empirical data. Non-responders were assumed to experience the cost of TPO-RAs for one cycle only, 
after which it was assumed that response would be assessable and non-responders would stop 
treatment.  
Because similar data were not available for romiplostim, time on treatment for romiplostim was assumed 
to be equal to that for eltrombopag. Time on treatment for non±TPO-RA treatments was taken from the 
clinical systematic review (19). In the absence of robust data and in order to avoid increasing model 
complexity, time on treatment was assumed to follow an exponential distribution for all non±TPO-RA 
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treatments. 
Risk of Bleeding: Patients in responder and non-responder states faced a risk of day-case bleeds and of 
bleeds requiring hospitalization (19). Bleeding risks were estimated using patient-level data from the 
eltrombopag clinical trial program as the number of events experienced per unit time for patients with 
HLWKHUSODWHOHWFRXQWVRU×109/L (Appendix Table 1). Bleeding events not expected to be 
associated with any medical intervention were not included in the model. Given a lack of data, bleeding 
rates were assumed to double when patients entered the long-term non-responder state following their 
last treatment, based on assumptions made in the NICE appraisal of romiplostim (20). Bleeds requiring 
hospitalization were subdivided into intracranial hemorrhage, gastrointestinal, and other bleeds using 
individual patient data from RAISE/EXTEND (Appendix Table 2). 
Mortality: ITP mortality was based on mortality rates associated with different ITP-related hospitalizations 
for severe bleeds (Appendix Table 3) (24). All-cause mortality was based on national statistics (25) and 
the average age and sex distribution were based on those observed in RAISE. 
Risk of Rescue: The rate of rescue conditional upon platelet level (i.e., for patients in a responder or non-
responder health state) was derived from RAISE/EXTEND, where the number of rescue events per unit 
WLPHZDVHVWLPDWHGIRUSDWLHQWVZLWKSODWHOHWOHYHOVDQGî9/L (Appendix Table 4). The 
proportions of each rescue type were also taken from RAISE and EXTEND (Appendix Table 5). It was 
assumed that these estimates were valid for both eltrombopag and romiplostim. This analysis of RAISE 
and EXTEND was restricted to countries with health care resources comparable to those in the UK. 
AE Rates: AEs were grouped into serious AEs and other AEs. AE rates were taken from the 
PDQXIDFWXUHU¶VVXEPLVVLRQRIURPLSORVWLPDVPLQLPDOLQIRUPDWLRQZDVIRXQGWKURXJKV\VWHPDWLFUHYLHZ
(Appendix Table 6) (21). AE rates for eltrombopag were assumed to be equal to those for romiplostim. 
Utility Values 
Utility values were mainly taken from a vignette study where health state descriptions were based on 
individual patient data collected via the ITP-patient assessment questionnaire (26). Time trade-off 
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techniques were used to elicit evaluations for these health states from 359 members of the UK general 
public. Disutilities associated with serious bleeds and AEs were obtained from the literature (Appendix 
Table 7) (27).  
Costs 
Drug acquisition costs were derived from British National Formulary 63 and reflect 2010/2011 pricing 
(accessed July 2012; no adjustment made) (Table 4) (28). The confidential discounts available to the 
NHS for romiplostim and eltrombopag through patient access schemes were also applied to these costs 
in order to reflect the true cost to the NHS. Eltrombopag and romiplostim doses used within the model 
were based on data from RAISE and the Kuter et al. trial (12, 15). To reflect dosing titration according to 
platelet response, doses were estimated for 4-week periods up to 23 weeks, beyond which the dose was 
assumed to be stable. Eltrombopag is available as a daily oral tablet and romiplostim as a weekly 
subcutaneous injection. Romiplostim vial wastage was incorporated into the model by calculating the 
number of vials each patient would require based on their baseline weight WKHGLVWULEXWLRQRILQGLYLGXDOV¶
baseline weights was obtained from RAISE). Dosing for non±TPO-RA treatments was taken from either 
the international consensus report (22) or the manufacturer¶V submission for romiplostim (21), and 
administration costs were based on NHS reference costs (29). Based on available data, it was estimated 
that 72% of romiplostim patients in the UK would be able to self-administer these drugs at home and 
would therefore incur no administration costs (30). Note that this may not be the case for other 
jurisdictions. Health state costs comprised the costs of treating bleeding events and follow-up costs 
(Table 4).  
Sensitivity Analyses 
A range of deterministic sensitivity analyses were performed where all key model inputs were varied 
(Appendix Table 8). Probabilistic sensitivity analyses were conducted by simultaneously sampling from 
estimated probability distributions of model parameters (Appendix Table 9) to obtain 1,000 sets of model 
estimates.  
RESULTS 
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Eltrombopag dominated romiplostim in both splenectomized and non-splenectomized patients in the 
probabilistic base case analyses (i.e., eltrombopag had 0.02 more quality-adjusted life-years [QALYs] and 
was less costly than romiplostim) (Table 5). In splenectomized patients, eltrombopag was associated with  
0.02 more QALYs than romiplostim and was £88,904  OHVVFRVWO\SHUSDWLHQWRYHUWKHSDWLHQW¶VOLIHWLPH,Q
non-splenectomized patients, eltrombopag was associated with 0.02 more QALYs and was £40,261 less 
costly per patient.  
Probabilistic sensitivity analysis results are presented on the cost-effectiveness planes in Figures 2A and 
2C. Cost-effectiveness acceptability curves demonstrated that, at a cost-effectiveness threshold of 
£20,000/QALY, the probability that eltrombopag is cost-effective versus romiplostim was 99% and 92% in 
splenectomized and non-splenectomized patients, respectively (Figs. 2B and 2D).  
This base-case finding of dominance was maintained in all of the deterministic sensitivity analyses 
performed with the exception of where the OR from the ITC of overall response was used to inform the 
relative efficacy of the TPO-RAs. In this analysis for splenectomized patients, eltrombopag was 
associated with  0.16 fewer QALYs than romiplostim and was £121,451 less costly per patient (Table 5). 
In non-splenectomized patients, eltrombopag was associated with 0.08 fewer QALYs and was £57,958 
less costly per patient. This resulted in incremental cost-effectiveness ratios (ICERs) of £754,830/QALY 
and £724,475/QALY for eltrombopag versus romiplostim in splenectomized and non-splenectomized 
patients, respectively. These ICERs were situated in the southwest quadrant of the cost-effectiveness 
plane and were therefore interpreted differently from ICERs in the northeast quadrant, which is where 
most ICERs of new treatments fall (Appendix Figure 1A and 1C). For ease of interpretation, these figures 
can be considered the ICERs for romiplostim versus eltrombopag, where romiplostim was more effective 
yet more costly. The cost-effectiveness acceptability curves for the probabilistic analysis are shown in 
Appendix Figure 1B and 1D. The ITC analyses therefore support the base case analyses and finds 
eltrombopag to be cost-effective at a cost-effectiveness threshold of £20,000 per QALY.  
 DISCUSSION 
There is a lack of evidence-based treatments available for cITP; however, the two TPO-RAs eltrombopag 
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and romiplostim represent a class of treatments supported by a relatively robust evidence base. The use 
of both TPO-RAs is supported by clinical trial programs that have demonstrated their long-term safety and 
efficacy in the treatment of patients with cITP (17, 31).  
Our base-case results suggest that eltrombopag is a cost-effective alternative to romiplostim. This result 
was relatively insensitive to the range of deterministic sensitivity analyses performed and was primarily 
driven by the lower total drug costs associated with eltrombopag. Furthermore, eltrombopag is 
administered as a once-daily tablet, whereas romiplostim is administered as a weekly subcutaneous 
injection. For simplicity, we made no attempt to incorporate the benefits of an oral therapy into this 
analysis. However, oral availability may be associated with a utility gain as well as benefits in terms of 
convenience and pharmacy/nursing capacity compared with an injection. 
A key assumption in our base case is that the two TPO-RAs have equivalent efficacy (i.e., a class effect 
exists). This assumption is consistent with clinical opinion (i.e., ITP guidelines do not distinguish between 
the two treatments). No head-to-head randomized trials were available to compare the two TPO-RAs. 
However, due to the presence of a common comparator and the availability of post-hoc analyses of 
RAISE, it was possible to conduct ITCs. A scenario analysis using results from the ITC of overall 
response allowed us to explore the impact of the uncertainty around the assumption of a class effect. 
Although performing ITCs is now a generally accepted method, these results should be interpreted with 
caution and in the context of the limitations and possible bias associated with them. There are several 
factors that increase the uncertainty of such an analysis in this particular case: 
 Differences in the patient populations of RAISE versus the two Kuter et al. trials (15, 30) regarding 
ITP duration, previous use of ITP medications, and use of concomitant medications.  
 Durable response was the primary endpoint of the romiplostim studies and a post-hoc analysis for 
eltrombopag. 2YHUDOOUHVSRQVHLVWKHVXPRI³GXUDEOH´DQG³WUDQVLHQW´UHVSRQVHV'XUDEOHUHVSRQVH
was similarly defined in the romiplostim trials and the eltrombopag post-hoc analysis: a response in 
RIWKHODVWHLJKWYLVLWVRIWKHWUHDWPHQWSHULRG+RZHYHUWKHGHILQLWLRQRI³WUDQVLHQWUHVSRQVH´ZDV
different: a transient response in the romiplostim trials required a response at any four weekly visits 
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during the study, whereas the eltrombopag analysis required four consecutive weekly visits. In a 
disease where platelet counts fluctuate, four consecutive responses are more difficult to achieve, and 
this is likely to have biased the ITC against eltrombopag. 
 While tapering or interruptions of concomitant ITP medications were not allowed during the last 12 
weeks of the romiplostim study, physicians in RAISE were encouraged to reduce concomitant ITP 
medications once a stable eltrombopag dose was achieved. This was more likely to occur towards 
the end of the trial, when durable response was assessed in the post-hoc analysis. Platelet count 
fluctuations are expected as a result of tapering ITP medications, and this most likely negatively 
impacted the response estimates for eltrombopag. 
 The number of durable and overall responders in the placebo arm of the romiplostim study was very 
low. As such, any ITC is very sensitive to small changes in this event rate.  
 The Evidence Review Group (ERG) for the NICE appraisal of elrombopag felt that a Bayesian rather 
than a Bucher approach should have been used to conduct the ITC in the overall RAISE population. 
However, due to the small amount of data available this was not found to be feasible by the ERG 
when analyzing splenectomized and non-splenectomized patients separately (32); therefore, it was 
not used in the current work. We note that in the overall population  alternative approaches applied to 
this data have led to outcomes consistent with the Bucher approach (33); therefore, we do not 
anticipate that this would have changed the overall outcome of the cost-effectiveness comparison.  
Given the limitations and possible bias surrounding a comparison of the TPO-RAs, we assumed a class 
effect in the base case and used results from the ITC in a sensitivity analysis. 
Where results from the ITC are used, eltrombopag is less effective but significantly less costly than 
romiplostim, with ICERs for eltrombopag versus romiplostim lying in the southwest quadrant of the cost-
effectiveness plane. In such situations, ICERs for eltrombopag that lie above (rather than below) the cost-
effectiveness threshold are considered to indicate cost-effectiveness (i.e., at a threshold of £20,000/QALY 
we want to observe at least £20,000 of savings per QALY lost). When the ITC is incorporated into the 
model, the resulting ICERs greatly exceed this threshold (i.e., eltrombopag offers savings of 
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>£100,000/QALY lost); therefore, eltrombopag is considered cost-effective. Results of this scenario 
analysis are reassuring for the decision maker given the uncertainty regarding the relative efficacy of 
eltrombopag and romiplostim. 
Other major areas of uncertainty were identified by the NICE committee (19). Sensitivity analyses show 
that conclusions were not sensitive to rescue or bleeding rates, or the use of alternative utility data. We 
made the simplifying assumption that patients who experience an overall response sustain platelet levels 
50×109/L and those who do not achieve response sustain platelet levels <50x109/L. Realistically, platelet 
levels will fluctuate in both groups and we will have exaggerated the benefits of response (vs. non-
response).  As comparator response rates are equal in the base case, this will have limited impact on 
incremental costs and QALYs. In the sensitivity analysis using data from the ITC, the analysis will 
exaggerate the health benefits and reduced costs associated with response and thereby bias the results 
in favour of romiplostim.  Patients receiving and responding to treatment with romiplostim were assumed 
to have a duration of treatment based on the empirical data from the eltrombopag trials. NICE considered 
this reasonable in the absence of other robust evidence (19); however, further information on treatment 
duration would improve the robustness of the analysis.  Finally, NICE considered that lower dosing of 
romiplostim in responders and eltrombopag in practice, and lower administration costs for romiplostim, 
may reduce costs (19). However, data to model these scenarios were not available and the best available 
data were used in the context of the current model. Despite these concerns, the committee concluded 
that using their preferred assumptions gave ICERs for eltrombopag compared to romiplostim of more than 
£250,000 saved per QALY lost, and that eltrombopag was a cost-effective use of NHS resources.  
Unfortunately, it is unlikely that additional efficacy data will become available to inform this decision 
problem. Given the low incidence of cITP, we suggest that it would be infeasible to recruit the estimated 
sample required to conduct a non-inferiority (>2,000 patients) or superiority randomized controlled trial 
(>3,000 patients) of romiplostim versus eltrombopag. The collection of observational data through the 
existing UK ITP registry may provide a useful source of information for future assessments of cITP 
treatments, particularly the long-term benefits of elevated platelet levels in a real-world setting. The 
current model compared the use of eltrombopag to romiplostim at the position in the treatment pathway in 
 16 
 
which romiplostim is currently used. Further work is required to define optimal treatment sequences in 
cITP and, in particular, whether it may be cost-effective to use the new TPO-RAs in sequence. This 
economic evaluation demonstrates that eltrombopag provides patients and clinicians with a cost-effective, 
oral treatment option for a disease for which there are few evidence-based treatments available. 
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FIGURE LEGENDS 
Figure 1. Model structure. LT, long term; NR, non-responder; Resp, responder; W, week. 
Figure 2. A) Probabilistic sensitivity analysis (1,000 simulations) and B) cost-effectiveness acceptability 
curves for splenectomized patients, and C) probabilistic sensitivity analysis (1,000 simulations) and D) 
cost-effectiveness acceptability curves for non-splenectomized patients. QALYs, quality-adjusted life-
years. 
Figure 1  
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Figure 2 
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Table 1. Number of previous treatments for chronic immune thrombocytopenia among participants in the 
RAISE Study (12). 
 Placebo (n=62) Eltrombopag (n=135) 
Two or more 50 (81%) 105 (78%) 
Three or more 32 (52%) 75 (56%) 
Four or more 20 (32%) 51 (38%) 
Five or more 11 (18%) 35 (26%) 
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Table 2. ITC of overall and durable responses. 
 Eltrombopag vs. 
placebo, 
OR (95% CI) 
Romiplostim vs. 
placebo, 
OR (95% CI) 
ITC of eltrombopag 
vs. romiplostim,  
OR (95% CI) 
Durable/sustained response 
Splenectomized patients  13.33 (1.66±107.43) 26.77 (1.52±472.41) 0.50 (0.01±17.32) 
Non-splenectomized patients  12.97 (3.72±45.26) 31.25 (3.81±256.24) 0.41 (0.04±4.80) 
Overall response  
Splenectomized patients  14.25 (2.98±68.02) 151.63 (8.39±2,741.84) 0.09 (0.00±2.52) 
Non-splenectomized patients  14.83 (5.53±39.76) 43.20 (9.27±201.33) 0.34 (0.06±2.14) 
CI, confidence interval; ITC, indirect treatment comparison; OR, odds ratio. 
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Table 3. Efficacy parameters. 
Drug Response proportion Time to response Duration of response 
(mean) 
Splenectomized Non-
splenectomized 
Eltrombopag 
76% 80% 
2 weeks (15 days) 
Log-normal 
distribution assigned 
Romiplostim 
76% 80% 
4 weeks (28 days) 
Equivalent to 
eltrombopag 
Rituximab 
57% 60% 
3.5 weeks (24.4 
days) 
24.6 months (748.4 
days) 
Azathioprine 
44% 46% 
16 weeks (112 
days) 
91 months (2,769.8 
days) 
Mycophenolate 
mofetil 51% 54% 
5 weeks (35 days) 
1.7 months (50.5 
days) 
Cyclosporine 
41% 43% 
3.5 weeks (24.5 
days) 
28.6 months (870.5 
days) 
Dapsone 
44% 46% 
5.1 weeks (35.5 
days) 
25.8 months (785.6 
days) 
Danazol 
35% 37% 
18 weeks (126 
days) 
145 months (4,413.3 
days) 
Cyclophosphamide 
82% 87% 
8.5 weeks (59.5 
days) 
41.7 months (1,268.8 
days) 
Vinca alkaloids 
56% 59% 
2.0 weeks (13.7 
days) 
41.7 months (1,268.8 
days) 
Rescue ± IVIg 
80% 84% 
3.5 days (assumed 
instantaneous in 
17.2 days (assumed 
1 month) 
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model) 
Rescue ± Anti-D 
41% 43% 
4.3 days (assumed 
instantaneous in 
model) 
42.7 days (assumed 
1 month) 
Rescue ± IV 
corticosteroid 40% 42% 
7.04 days (assumed 
instantaneous in 
model) 
Assumed 1 month 
Rescue ± platelet 
transfusion 41% 43% 
Assumed 
instantaneous in 
model 
Assumed 1 month 
IV, intravenous; IVIg, intravenous immunoglobulin. 
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Table 4. Costs used in the economic model. 
Drug Acquisition cost Size (mg) Administration 
cost 
NHS reference 
costs 
2010/2011 BNF 63 (28) HRG code 
Eltrombopag* £770.00 700 (28 x 25) N/A N/A 
Romiplostim* £482.00 0.25 SB12Z £204.81 
Azathioprine £5.04 1,400 
N/A N/A 
Mycophenolate mofetil £35.00 25,000 
Cyclosporine £13.80 750 
Dapsone £54.56 2,800 
Danazol £16.38 6,000 
Cyclophosphamide £20.20 5,000 
Vincristine £13.47 1 SB12Z £204.81 
Vinblastine £13.09 10 SB12Z £204.81 
Rescue ± IVIg £45.00 1,000 XD34Z £1,235.34 
Rescue ± Anti-D £46.50 0.3 XD34Z £1,235.34 
Rescue ± IV 
corticosteroid 
£5.73 25 SB14Z £330.59 
Cost of treating bleeds 
Bleed type HRG code NHS reference costs 2010/2011 
Day-case bleed 
SA08F Other hematological or 
splenic disorders without CC ± day 
case 
£302.81 
Gastrointestinal bleed 
FZ38 Gastrointestinal hemorrhage, 
unspecified 
Inpatient £1,553 (weighted average over 
HRG codes FZ38D, FZ38E, and FZ38F) 
Intracranial 
hemorrhage 
Intracranial hemorrhage (non-
traumatic), unspecified 
Inpatient £3,451 (weighted average over 
HRG codes AA23A and AA23B) 
Other bleed requiring Assumed equal to FZ38 Inpatient £1,553 
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hospitalization 
Follow-up costs (applied every 4 weeks to all patients) 
 
HRG code NHS reference costs 2010/2011 
Hematologist 
consultation 
303 Clinical hematology, consultant 
led: First attendance non-admitted 
face to face 
£147.53 
Blood test DAP823 Hematology £3.00 
Biochemistry DAP841 Biochemistry £1.00 
*Discounts were applied.  
BNF, British National Formulary; CC, complications and comorbidities; HRG, Health Resource Group; IV, 
intravenous; IVIg, intravenous immunoglobulin; N/A, not available; NHS, National Health Service. 
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Table 5. Cost-effectiveness results for the base-case (probabilistic) and deterministic sensitivity analysis 
incorporating indirect efficacy estimates. 
Drug 
Total 
costs  
Total 
QALYs 
Incremental 
costs 
Incremental 
QALYs 
ICERs (£/QALY) 
vs. romiplostim 
Base case (probabilistic) 
Splenectomized       
Eltrombopag £322,900 
 
14.83 
  
Referent  
Romiplostim £411,804 
 
14.81 £88,904 í Dominanted  
Non-splenectomized       
Eltrombopag £236,339 
 
15.33 
  
Referent  
Romiplostim £276,600 
 
15.31 £40,261 í Dominanted  
Incorporating indirect efficacy estimates (probabilistic) 
Splenectomized       
Eltrombopag £323,209  14.79   Referent  
Romiplostim £444,660  14.95 £121,451 0.16 £754,830 
Non-splenectomized       
Eltrombopag £231,215  15.34   Referent 
Romiplostim £289,173  15.42 £57,958 0.08 £724,475 
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SW, southwest 
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SUPPLEMENTAL MATERIALS 
Differences from the National Institute for Health and Care Excellence (NICE) Submission 
5HVXOWVSUHVHQWHGLQWKLVPDQXVFULSWGLIIHUIURPWKHEDVHFDVHLQWKHPDQXIDFWXUHU¶VVXEPLVVLRQWR1,&(
[1]. The base case analysis in the original NICE submission used a significant proportion of data 
from TA221 to ensure consistent decision-making between appraisals. In this manuscript the 
³DOWHUQDWLYHDQDO\VLV´SUHVHQWHGLQWKHPDQXIDFWXUHU¶VVXEPLVVLRQWR1,&(IRUPVWKHEDVHFDVH. 
This alternative analysis was considered to be more appropriate by the Evidence Review Group (ERG) 
DQGE\WKH1,&(FRPPLWWHHZKRFRQVLGHUHGWKLVWREH³the most valid analysis because the modelling 
applied data derived directly from the pivotal trials of HOWURPERSDJDQGWKHPDQXIDFWXUHU¶VRZQV\VWHPDWLF
review´,QDGGLWLRQWKHEDVHFDVHDQDO\VLVLQWKH1,&(VXEPLVVLRQZDVEDVHGRQGHWHUPLQLVWLFDQDO\VHV
whereas those in our manuscript are based on probabilistic analyses, in line with methodological best 
practice. 
 
Probability of Receiving Each Treatment in the Treatment Pathway 
The probability of receiving each drug, based on the National Institute for Health and Care Excellence 
(NICE) 2008 submission for romiplostim, was 59% for azathioprine, 37% for mycophenolate mofetil, 4% 
for cyclosporine, 7% for danazol, 48% for dapsone, 2% for cyclophosphamide, and 5% for vinca alkaloids 
[2]. 
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Appendix Table 1. Bleed rates conditional upon platelet response. 
Platelet count and hospital admission classification Data from RAISE/EXTEND [3, 4] 
Splenectomized Non-splenectomized 
Platelets 50×109/L ± inpatient* 0.002 0.002 
Platelets 50×109/L ± day case 0.086 0.028 
Platelets <50×10
9
/L ± inpatient* 0.008 0.008 
Platelets <50×10
9
/L ± day case 0.341 0.214 
Source 
IPD analysis of RAISE/EXTEND, rate per  
4-week cycle 
IPD, individual patient data. 
* Due to the relatively low number of inpatient bleed occurrences, data were pooled across splenectomized and non-splenectomized patients. 
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Appendix Table 2. Distribution of bleed types among bleeds requiring hospitalization.* 
Bleed type requiring hospitalization Platelets <50×10
9
/L, 
Proportion of all bleeds requiring 
hospitalization 
3ODWHOHWVî9/L, 
Proportion of all bleeds requiring 
hospitalization 
Other bleed (coagulation disorder) 0.63 0.71 
GI hemorrhage (GI bleeding) 0.19 0.29 
Intracranial hemorrhage  0.19 0.00 
GI, gastrointestinal; IPD, individual patient data.  
* IPD analysis of RAISE and EXTEND [3, 4]; includes splenectomized and non-splenectomized patients. 
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Appendix Table 3. Proportion of deaths among patients with ITP-related hospitalization for severe bleed [5]. 
Discharge condition Mortality rate, % (95% CI) 
Other bleed (coagulation disorder) 1.7 (1.4±2.0) 
GI hemorrhage (GI bleeding)  4.6 (2.7±6.4) 
Intracranial hemorrhage  13.2 (9.8±16.6) 
CI, confidence interval; GI, gastrointestinal; ITP, immune thrombocytopenia.   
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Appendix Table 4. Rates of rescue conditional on platelet response estimated from RAISE/EXTEND IPD. 
 Splenectomized Non-splenectomized 
3ODWHOHWV×109/L 0.05 0.01 
Platelets <50×10
9
/L 0.32 0.14 
Source IPD analysis of RAISE/EXTEND [3,4], rate per 4-week cycle 
IPD, individual patient data. 
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Appendix Table 5. Distribution of rescue types among patients requiring rescue. 
 Scenario 1 
Rescue medication 
Platelet count <50×10
9
/L Platelet count 50×109/L 
Splenectomized Non-
splenectomized 
Splenectomized Non-
splenectomized 
IVIg 0.51 0.55 0.31 0.50 
Anti-D 0.02* 0.18 0.00 0.14 
IV steroid 0.11 0.07 0.14 0.36 
Platelet transfusion 0.36 0.20 0.55 0.00 
Source RAISE/EXTEND [3,4] IPD analysis 
IPD, individual patient data; IV, intravenous; IVIg, intravenous immunoglobulin. 
* The very small amount of anti-D use observed in splenectomized patients in the IPD was retained in the model; however, anti-D is not 
recommended for use in splenectomized patients [6, 7]. 
  
 38 
 
Appendix Table 6. 4-week probabilities of adverse events [2]. 
Drug Event probability* 
Serious AEs Other AEs 
Eltrombopag 3%

 31%

 
Romiplostim 3% 31% 
Rituximab 3% 0% 
Azathioprine 15% 24% 
Mycophenolate mofetil 15% 24% 
Cyclosporine 15% 24% 
Dapsone 11% 24% 
Danazol 16% 35% 
Cyclophosphamide 21% 30% 
Vinca alkaloids 21% 30% 
Rescue ± IVIg 2% 0% 
Rescue ± Anti-D 3% 0% 
Rescue ± IV corticosteroid 3% 70% 
AE, adverse event; IV, intravenous; IVIg, intravenous immunoglobulin. 
*
 
Mid-point used where range reported. 
 
Assumed to be the same as romiplostim, as there was no appreciable difference in safety between thrombopoietin-receptor agonists. Note: 
Platelet transfusions were assumed to be associated with QRULVNRI³RWKHU´AEs and a ULVNRI³VHULRXV´AEs. 
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Appendix Table 7. Base-case utilities. 
Health state Mean Standard error Source 
No bleed, sufficient platelets 0.863 0.0079 
Szende et al 2010 [8] 
Bleed, sufficient platelets 0.734 0.0100 
No bleed, low platelets 0.841 0.0100 
Bleed, low platelets 0.732 0.0100 
Intracranial hemorrhage (2±6 months)* 0.038 0.0243 
Corticosteroid treatment AE 0.758 0.0106 
Gastrointestinal bleed* 0.450 0.0561 Leontiadis et al 2007 [9] 
Other bleed requiring inpatient treatment* 0.450 0.0561 Assumption 
Four-week disutility associated with SAEs (associated 
with eltrombopag, romiplostim, and rituximab)

 
0.100 0.025 
NICE TA221 [2] 
 
Four-week disutility associated with SAEs (associated 
with all other non-rescue treatments) 
0.400 0.100 
Four-week disutility associated with SAEs (associated 
with rescue treatments) 
0.10 0.025 
Four-week disutility associated with other AEs 0.10 0.025 
AEs, adverse events; SAEs, serious adverse events.  
* Intracranial hemorrhage was assumed to impact utility for 4 months, and gastrointestinal bleeds and other bleeds were assumed to impact utility 
for one cycle (4 weeks).  
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 
All AEs were assumed to last 4 weeks.  
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Appendix Table 8. Deterministic sensitivity analyses. 
Deterministic sensitivity analyses 
Treatment pathway TPO-RA received prior to rituximab 
TPO-RA as last active treatment in pathway 
Response rates [3] OR of 1.0 for TPO-RA comparison, baseline overall response as 
per RAISE post-hoc analysis  
OR taken from ITC, applied to baseline overall response as per 
RAISE post-hoc analysis 
Time on treatment Time on treatment for responders, log-logistic 
Time on treatment for responders, gamma 
Time on treatment for all patients, Gompertz 
Time on treatment for all patients, log-logistic 
Time on treatment for all patients, Weibull 
Mortality  Mortality modeled via platelet level rather than bleeds  
Rescue rates [2±4] RAISE/EXTEND UDWHí 
Midpoint RAISE/EXTEND and TA221 
TA221 
TA221 +25%  
Bleeding rates [2±4] RAISE/EXTEND rate ±25% 
Midpoint RAISE/EXTEND and TA221 
TA221 
TA221 +25% 
Bleed risk in final non-responder state  Same as other non-responder states 
Utilities SF-6D data from the RAISE/EXTEND clinical trial program* 
Costs All patients receive romiplostim at outpatient visit 
No price discount for eltrombopag 
Romiplostim dose from Bussel et al 2009 extension trial [10]  
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Decision-maker parameters Discount rate = 0% 
Discount rate = 6% 
Time horizon of 6 months 
Time horizon of 5 years 
Time horizon of 10 years 
Time horizon of 20 years 
ITC, indirect treatment comparison; OR, odds ratio; SF-6D, six-dimensional health state short form; TPO-
RA, thrombopoietin-receptor agonist. 
* SF-36 (36-item Short-Form Health Survey) assessments pooled from RAISE [3] and EXTEND [4] 
mapped to the SF-6D are shown in Appendix Table 11.  
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Appendix Table 9. Distributions used for probabilistic sensitivity analysis. 
Parameter Distribution, parameterization 
Probability of receiving 
each treatment 
Beta, parameterized using parameter estimates from TA221 [2] 
Response rates Eltrombopag response: beta, event rates and sample sizes obtained from 
RAISE [3] IPD. For OR comparing romiplostim and eltrombopag, SE of log 
OR = 1.0 to reflect uncertainty regarding relative efficacy of treatments 
Non±TPO-RA: beta distribution, parameters taken from appropriate study 
Time to response Gamma, assume SE = 0.25*mean 
Time on treatment TPO-RA: multivariate normal distribution assumed for parameters of 
parametric distributions, covariance matrix obtained from survival analysis of 
RAISE/EXTEND IPD 
Non±TPO-RA: gamma, assume SE = 0.25*mean 
Rescue rates Gamma, assume variance equal to mean 
Distribution of rescue 
types 
Dirichlet taken directly from IPD for RAISE/EXTEND  
Bleed rates Gamma, assume variance equal to mean 
Proportion of patients 
experiencing each bleed 
type 
Dirichlet, taken directly from IPD for RAISE/EXTEND  
Rates of mortality 
conditional upon bleed 
%HWDĮDQGȕGHULYHGIURPHYHQWVDQGVDPSOHVL]HLQ'DQHVHet al 2009 [5] 
Utilities ± health states 
and bleeds 
Log-normal distribution use to model decrement from full health, 
parameterized using mean and SEs from Szende et al 2010 [8] and 
Leontiadis et al 2007 [9] 
Adverse event rates Beta: parameters obtained from TA221 [2] 
Adverse event disutilities Log-normal distribution use to model decrement, SE assumed equal to 
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0.25*mean 
Eltrombopag and 
romiplostim mean doses 
Log-normal distribution, mean and SEs available from RAISE/EXTEND IPD 
for eltrombopag, and from Kuter et al 2008 [11] and Bussel et al 2009 [10] for 
romiplostim 
Proportion of patients 
receiving romiplostim as 
home administration 
%HWDĮDQGȕGHULYHGIURPHYHQWVDQGVDPSOHVL]HLQ.XWHU et al 2010 [12] 
Cost of bleeds, long-term 
follow-up, and treatment 
administration 
Gamma used for unit costs, SE assumed equal to 0.25*mean. Dirichlet used 
for distribution of activity, directly parameterized using NHS reference cost 
activity rates 
IPD, individual patient data; NHS, National Health Service; OR, odds ratio; SE, standard error; TPO-RA, 
thrombopoietin-receptor agonist. 
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Appendix Table 10. SF-6D values.* 
Health state Splenectomized Non-splenectomized 
No bleed, sufficient platelets 0.737 0.761 
Bleed, sufficient platelets 0.693 0.761 
No bleed, low platelets 0.712 0.738 
Bleed, low platelets 0.666 0.738 
SF-6D, six-dimensional health state short form. 
* Assessments from the 36-item Short-Form Health Survey (SF-36) pooled from RAISE and EXTEND. 
Values used that were identical to base case are not shown.  
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Appendix Figure 1. A) Probabilistic sensitivity analysis (1,000 simulations) and B) cost-effectiveness acceptability curves for splenectomized 
patients, and C) probabilistic sensitivity analysis (1,000 simulations) and D) cost-effectiveness acceptability curves for non-splenectomized 
patients. QALYs, quality-adjusted life-years. Data based on indirect treatment comparison, probabilistic analysis. 
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